The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
Open accessAbstract
Purpose: Dasatinib is effective therapy for chronic myeloid leukemia (CML) after imatinib failure. In this study, we investigate the efficacy of dasatinib as initial therapy for patients with CML in early chronic phase. Patients and Methods: Patients with newly diagnosed CML in early chronic phase were randomly assigned to receive dasatinib 100 mg once daily or 50 mg twice daily as initial therapy. Results: Among 50 patients observed for at least 3 months, 49 patients (98%) achieved a complete cytogenetic response (CCyR), and 41 patients (82%) achieved a major molecular response (MMR). Responses occurred rapidly, with 94% of patients achieving CCyR by 6 months. There was no difference in response rate by treatment arm. The projected event-free survival rate at 24 months is 88%, and all patients are alive after a median follow-up time of 24 months. Grade ≥ 3 neutropenia and thrombocytopenia occurred in 21% and 10% of patients, respectively. Nonhematologic toxicity was usually grade 1 to 2. There was no significant difference in toxicity between the two arms, and the actual median dose at 12 months was 100 mg (range, 20 to 100 mg). Conclusion: Dasatinib is an effective agent for the initial management of CML in early chronic phase, producing high rates of CCyR and MMR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradeen, H. A., Eide, C. A., O'Hare, T., Johnson, K. J., Willis, S. G., Lee, F. Y., Druker, B. J., & Deininger, M. W. (2006) · Blood · doi:10.1182/blood-2006-02-004580 · Cited by 393
Cited by
Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
Self-citationSteegmann, J. L., Baccarani, M., Breccia, M., Casado, L. F., García-Gutiérrez, V, Hochhaus, A., Kim, D.-W., Kim, T. D., Khoury, H. J., Le Coutre, P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.104 · Cited by 482
Cortes, J. E., Kim, D.-W., Kantarjian, H. M., Brümmendorf, T. H., Dyagil, I., Griskevicius, L., Malhotra, H., Powell, C., Gogat, K., Countouriotis, A. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7522 · Cited by 466
Self-citationKantarjian, H., O'Brien, S., Jabbour, E., Garcia-Manero, G., Quintas-Cardama, A., Shan, J., Rios, M. B., Ravandi, F., Faderl, S., Kadia, T., et al. (2012) · Blood · doi:10.1182/blood-2011-08-358135 · Cited by 334
Self-citationNaqvi, K., Jabbour, E., Skinner, J., Anderson, K., Dellasala, S., Yilmaz, M., Ferrajoli, A., Bose, P., Thompson, P., Alvarado, Y., et al. (2020) · Cancer · doi:10.1002/cncr.32504 · Cited by 135
Self-citation
Metadata
- Authors
- Cortes, J. E., Jones, D., O'Brien, S., Jabbour, E., Ravandi, F., Koller, C., Borthakur, G., Walker, B., Zhao, W., Shan, J., & Kantarjian, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-01-20
- Volume
- 28
- Issue
- 3
- Pages
- 398-404
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2168633862
- Cited by
- 241
- References
- 1
- FWCI
- 23.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia. https://app.cochat.ai/papers/10.1200/jco.2009.25.4920
- The paper
- Cortes, J. E., Jones, D., O'Brien, S., Jabbour, E., Ravandi, F., Koller, C., Borthakur, G., Walker, B., Zhao, W., Shan, J., & Kantarjian, H. (2010). Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.25.4920
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
